Los Angeles, CA -- (SBWire) -- 04/26/2019 --Paclitaxel is a mitotic inhibitor used in Cancer chemotherapy; Paclitaxel was discovered in 1962 as a result of a U.S. National Cancer Institute-funded screening program; Monroe Wall and Mansukh Wani isolated the drug from the bark of the Pacific yew, Taxus brevifolia, and named it "taxol".
In the last several years, global market of Paclitaxel developed rapidly, with an average growth rate of 12.3%. In 2017, global revenue of Paclitaxel is nearly 80 M USD; the actual production is about 2600 Kg.
The classification of Paclitaxel includes Natural Paclitaxel API and Semi-Synthetic Paclitaxel API, and the proportion of Natural Paclitaxel API in 2017 is about 31.3%, and the proportion is decreasing trend from 2012 to 2017.
The global Paclitaxel market was 90 million US$ in 2018 and is expected to 160 million US$ by the end of 2025, growing at a CAGR of 8.7% between 2019 and 2025.
Get PDF of this report template: https://www.qyresearch.com/sample-form/form/1084744/global-paclitaxel-market
This report studies the Paclitaxel market size (value and volume) by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.
Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Paclitaxel in these regions, from 2014 to 2025, covering
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia and Turkey etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil etc.)
Middle East and Africa (Egypt and GCC Countries)
The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in this market include
Phyton
ScinoPharm
Novasep
Samyang
Polymed
TAPI (Teva)
Fresenius-kabi
Huiang biopharma
Southpharma
Yunnan Hande
Hainan Yew Pharm
Jiangsu Yew Biotechnology
By the product type, the market is primarily split into
Natural Paclitaxel API
Semi-synthetic Paclitaxel API
By the end users/application, this report covers the following segments
Ovarian Cancer
Cervical Cancer
Breast Cancer
Other
Get Full Report Now at USD 3,3500: https://www.qyresearch.com/settlement/pre/fb623c6c8221d12b324f9153fe4a7e94,0,1,Global%20Paclitaxel%20Market%20Report,%20History%20and%20Forecast%202014-2025,%20Breakdown%20Data%20by%20Manufacturers,%20Key%20Regions,%20Types%20and%20Application
Benefits of Purchasing QY Research Report
- Analyst Support: Get you query resolved from our expert analysts before and after purchasing the report
- Customer's Satisfaction: Our expert team will assist with all your research needs and customize the report
- Inimitable Expertise: Analysts will provide deep insights about the reports
- Assured Quality: We focus on the quality and accuracy of the report
About QYResearch
QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.
Paclitaxel Market Is Predicted to Reach at a 160 Million USD by the End of 2025, with a CAGR of 8.7%: QY Research
QYResearch is a leading market research publisher which pursuits high product quality with the belief that quality is the soul of business and consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience.